Key facts
- This page summarizes Peter M. Neupert's Form 4 filing for Adaptive Biotechnologies Corp (ADPT).
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 12 Mar 2025, 19:47.
Peter M. Neupert - 10 Mar 2025 Form 4 Insider Report for Adaptive Biotechnologies Corp (ADPT)
- Reporting relationship
- Director
- Issuer ticker
- ADPT
- Reported as of
- 10 Mar 2025
- Net transaction value
- +$133,000
- SEC form
- 4
- Accepted by SEC
- 12 Mar 2025, 19:47:38 UTC
- Prior SEC filing
- 06 Mar 2025
- Next SEC filing
- 16 May 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Peter M Neupert by Kyle Piskel, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Peter M. Neupert filed Form 4 for Adaptive Biotechnologies Corp (ADPT) on 12 Mar 2025.
Change
- Previous filing in this sequence was filed on 06 Mar 2025.
- Current net transaction value: +$133,000.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ADPT
transaction
Common Stock
Options Exercise
- Transaction value
- $203,500
- Shares
- +50,000
- Change %
- +27%
- Price
- $4.07
- Shares after
- 234,690
- Date
- 10 Mar 2025
- Ownership
- Direct
ADPT
transaction
Common Stock
Sale
- Transaction value
- $70,500
- Shares
- -10,000
- Change %
- -4.3%
- Price
- $7.05
- Shares after
- 224,690
- Date
- 10 Mar 2025
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ADPT
transaction
Derivative
Stock Option (right to buy)
Options Exercise
- Transaction value
- $0
- Shares
- -50,000
- Change %
- -100%
- Price
- $0.000000
- Shares after
- 0
- Date
- 10 Mar 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 50,000
- Exercise price
- $4.07
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $7.03 to 7.07, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
Footnote F2
The option was fully vested and exercisable.